

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Results from the Phase III KEYNOTE-811 trial demonstrated a higher overall response rate with first-line chemotherapy/trastuzumab and pembrolizumab compared to chemotherapy/trastuzumab and placebo for which of the following subsets of patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) cancer?

 - a. Patients with adenocarcinoma histology only
 - b. Patients with squamous cell histology only
 - c. Patients with either adenocarcinoma or squamous cell histology
2. Which of the following proteins is the target of the novel antibody zolbetuximab, currently being investigated for the treatment of gastroesophageal cancers?

 - a. GFR2b
 - b. HER2
 - c. Claudin 18.2
 - d. PD-L1
3. Results of the Phase III CheckMate 577 trial evaluating nivolumab versus placebo as adjuvant therapy for patients at high risk with resected esophageal or GEJ cancer demonstrated a significant benefit in disease-free survival with nivolumab in which group?

 - a. Overall intent-to-treat population
 - b. Only patients with tumor-cell PD-L1 expression $\geq 1\%$
 - c. Only patients with tumor-cell PD-L1 expression $< 1\%$
4. Which of the following observations was reported in the efficacy results from the Phase III FIGHT trial assessing the addition of bemarituzumab versus placebo to FOLFOX as first-line therapy for patients with FGFR2b-positive advanced gastric or GEJ adenocarcinoma?

 - a. Similar progression-free survival outcomes on both study arms
 - b. Improved progression-free outcomes on the bemarituzumab arm